

EXHIBIT 10

Dennis Weisenburger, M.D.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS) MDL No. 2741
LIABILITY LITIGATION,)
) Case No.
)
_____) 16-md-02741-VC

This document relates)
to:)
)
Hardeman v. Monsanto)
(3:16-cv-00525-VC))
_____)

Video Deposition of DENNIS
WEISENBURGER, M.D., held at 700 West
Huntington Drive, Monrovia, California,
commencing at 8:35 a.m., on Thursday,
December 20, 2018, before Lisa Moskowitz,
California CSR 10816, RPR, CRR, CLR, NCRA
Realtime Systems Administrator.

- - -

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
Deps@golkow.com

Page 2

1 APPEARANCES:
 2
 3 ANDRUS WAGSTAFF
 4 BY: KATHRYN M. FORGIE
 kathryn.forgie@andruswagstaff.com
 1901 Harrison Street, Suite 1100
 5 Oakland, California 94612
 (310) 339-8214
 6
 Counsel for Plaintiff
 7
 8
 9 ARNOLD & PORTER KAYE SCHOLER, LLP
 BY: JULIE DU PONT
 julie.dupont@arnoldporter.com
 10 250 West 55th Street
 New York, New York 10019-9710
 11 (212) 836-8572
 Counsel for Defendant Monsanto
 12
 13
 14 ARNOLD & PORTER KAYE SCHOLER, LLP
 BY: KATHRYN M. PODSIADLO
 kathryn.podsiadlo@apks.com
 15 777 South Figueroa Street, 44th Floor
 Los Angeles, California 90017-5844
 16 (213) 243-4273
 17
 Counsel for Defendant Monsanto
 18
 19
 20 VIDEOGRAPHER:
 21 RYAN SCHAEFER,
 GOLKOW LITIGATION SERVICES
 22
 23 ---
 24
 25

Page 4

1 DEPOSITION EXHIBITS (Cont'd)
 2 NUMBER DESCRIPTION PAGE
 3 11 Castillo Article 87
 4 12 Zuckerman Article 100
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25

Page 3

1 INDEX
 2 EXAMINATION OF PAGE
 3 DENNIS WEISENBURGER, M.D.
 4 By Ms. Du Pont 6, 113
 5 By Ms. Forgie 106
 6
 7
 8
 9 DEPOSITION EXHIBITS
 10 NUMBER DESCRIPTION PAGE
 11 1 Monsanto Company's Notice to
 Take Oral and Videotaped
 12 Deposition of Dr. Dennis
 Weisenburger
 13
 14 2 Dr. Weisenburger Materials 8
 List, November 13, 2018
 15 3 Curriculum Vitae 8
 16 4 Handwritten Notes 15
 17 5 Retention Agreement Expert
 Opinions and Testimony 18
 18
 19 6 Addendum to Dr. Weisenburger's 19
 Reference List
 20 7 Expert Report of Dr. Dennis 21
 Weisenburger
 21
 22 8 IARC Monograph on Hepatitis C 54
 23
 24 9 Study by Dal Maso 62
 25 10 Article by Mahale 70

Page 5

1 MONROVIA, CALIFORNIA
 2 THURSDAY, DECEMBER 20, 2018, 8:35 A.M.
 3
 4 THE VIDEOGRAPHER: We're now on
 5 record. My name is Ryan Schaefer. I'm
 6 a videographer for Golkow Litigation
 7 Services.
 8 Today's date is December 20,
 9 2018, and the time is 8:35 a.m. This
 10 video deposition is being held at
 11 700 West Huntington Drive, Monrovia,
 12 California, in the matter of Hardeman
 13 versus Monsanto Company, case number
 14 3:16-cv-00525-VC for the U.S. District
 15 Court, Northern District of California.
 16 The deponent is Dr. Dennis Weisenburger.
 17 Counsel will be noted on the
 18 stenographic record and will counsel
 19 please identify themselves.
 20 MS. FORGIE: Kathryn Forgie of
 21 Andrus Wagstaff for the plaintiff
 22 Mr. Hardeman.
 23 MS. DU PONT: Julie du Pont of
 24 Arnold Porter on behalf of Monsanto.
 25 MS. PODSIADLO: Kathryn

Page 10

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

25 [REDACTED]

Page 11

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

25 [REDACTED]

Page 12

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 Q. You also reviewed the testimony of

12 several of Mr. Hardeman's doctors, Dr. [REDACTED],

13 [REDACTED], and [REDACTED]; is that right?

14 A. Yes.

15 Q. You had the opportunity to review

16 the depo transcript of Mr. Hardeman; right?

17 A. Yes.

18 Q. Did you review the deposition

19 transcript of his wife's deposition?

20 A. Yes.

21 Q. That just wasn't listed here, but

22 you did, in fact, review it?

23 A. Yes.

24 MS. FORGIE: We'd like to add

25 it.

Page 13

1 MS. DU PONT: Okay.

2 MS. FORGIE: I thought it was

3 on there.

4 BY MS. DU PONT:

5 Q. Since you received -- since you

6 wrote your report, you've also had the

7 opportunity to review the reports of

8 Dr. Arbor, Grossbard, Levine and Steidl; is

9 that right?

10 A. Yes.

11 Q. Do you know Dr. Levine?

12 A. Yes.

13 Q. You worked together at the City of

14 Hope; right?

15 A. She was my boss.

16 Q. She was your boss but now she isn't

17 your boss?

18 A. Yes. She stepped down from her

19 position.

20 Q. Did you respect her?

21 A. Yes.

22 Q. Did you consider her to be a highly

23 qualified oncologist?

24 A. Yes.

25 Q. And you mentioned you also know

Page 14

1 Dr. Arbor and you respect him as well?
 2 A. Yes.
 3 Q. And, again, you believe him to be a
 4 highly qualified pathologist?
 5 A. Yes.
 6 Q. And how do you know Dr. Arbor?
 7 A. Just we move in the same circles.
 8 He does the same thing I do. We always see
 9 each other at meetings. He also did his
 10 training at the City of Hope. We have kind
 11 of a common bond there.
 12 Q. Okay. Do you know Dr. Michael
 13 Grossbard?
 14 A. I don't.
 15 Q. And do you know Dr. Steidl?
 16 A. Yes.
 17 Q. I may be pronouncing his name
 18 wrong.
 19 A. Steidl.
 20 Q. How do you know him?
 21 A. Sort of the same way, through just
 22 we do -- we've done research together. You
 23 know, we see each other at meetings. He's
 24 visited City of Hope. So we know each other
 25 through our academic endeavors.

Page 15

1 Q. Okay. And do you respect him?
 2 A. Yes.
 3 Q. Do you consider him to be highly
 4 qualified in his field?
 5 A. Yes.
 6 Q. Okay. You can set that aside.
 7 We've marked as Exhibit 4 your invoice for
 8 your work in the Hardeman matter.
 9 (Exhibit Number 4 was marked
 10 for identification.)
 11 BY MS. DU PONT:
 12 Q. Can you take a look at that?
 13 A. Yes.
 14 Q. It looks like between October 20,
 15 2018, and November 20, 2018, you billed
 16 32-and-a-half hours; is that right?
 17 A. Yes.
 18 Q. At \$500 an hour?
 19 A. Yes.
 20 Q. And so as of November 20, 2018 you
 21 had made \$16,250?
 22 A. Yes.
 23 Q. And have you worked on
 24 Mr. Hardeman's case since November 20, 2018?
 25 A. Yes.

Page 16

1 Q. How many hours have you billed?
 2 A. 32.5. 35.5.
 3 Q. So you worked an additional three
 4 hours or you --
 5 A. 35 hours. 35½ hours.
 6 Q. In addition to the 32.5 you already
 7 billed. Okay.
 8 MS. PODSIADLO: 17,750.
 9 BY MS. DU PONT:
 10 Q. You've earned an additional \$17,750
 11 on Mr. Hardeman's case since November 20?
 12 A. If the math is correct, yes.
 13 Q. So in total you've made \$34,000
 14 working on Mr. Hardeman's case to date?
 15 A. Sounds right.
 16 Q. Okay. And that additional
 17 35½ hours, how did you spend that time?
 18 A. Mostly reading additional materials
 19 on hepatitis C and hepatitis B and other
 20 topics.
 21 Q. And why did you feel the need to
 22 read additional materials on hep C and hep B
 23 and other topics?
 24 A. It's not an area I'm particularly
 25 an expert in; so I had to go back and learn

Page 17

1 a lot about hepatitis C and hepatitis B.
 2 When I read the Monsanto expert reports,
 3 there were some issues that I needed to
 4 research and understand.
 5 So I pulled additional articles
 6 that were referenced in their reports.
 7 Q. Did counsel for plaintiff provide
 8 you with any additional articles on hep B
 9 and hep C?
 10 A. No.
 11 Q. [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 A. We looked at -- into autoimmune
 15 disease. I looked into eczema. I guess
 16 those were the main things.
 17 Q. Okay. Now, you can set your
 18 invoice aside. We've marked as Exhibit 5
 19 your retention agreement with Andrus
 20 Wagstaff.
 21 Do you see that?
 22 A. Yes.
 23 Q. Do you understand this to be your
 24 retention agreement in the Roundup
 25 litigation as well as your W-9 which is on

Page 18

1 the second page?
 2 A. Yes.
 3 (Exhibit Number 5 was marked
 4 for identification.)
 5 BY MS. DU PONT:
 6 Q. You can set that aside.
 7 MS. FORGIE: I'd like to
 8 redact. I didn't realize his social
 9 security number was in there. I'd like
 10 to redact that from the deposition.
 11 Can we do that on the exhibit?
 12 MS. DU PONT: Sure.
 13 MS. FORGIE: Can we do that
 14 now?
 15 MS. DU PONT: Yeah. Do you
 16 want to take a brief break?
 17 MS. FORGIE: Yeah, that's kind
 18 of a big deal.
 19 THE VIDEOGRAPHER: The time is
 20 8:49 a.m., and we are off the record.
 21 (Recess taken from 8:50 a.m.
 22 to 8:50 a.m.)
 23 THE VIDEOGRAPHER: The time
 24 is now 8:50 a.m., and we are back on
 25 the record.

Page 19

1 MS. FORGIE: Just for the
 2 record, we -- by agreement of all
 3 counsel, we had the court reporter
 4 redact Dr. Weisenburger's social
 5 security number from Exhibit 5. Thank
 6 you.
 7 MS. DU PONT: Okay.
 8 BY MS. DU PONT:
 9 Q. Moving on, marked as Exhibit 6 is
 10 your addendum to your reference list.
 11 (Exhibit Number 6 was marked
 12 for identification.)
 13 BY MS. DU PONT:
 14 Q. When did you prepare this addendum?
 15 A. It would have been last week.
 16 Q. So it was prepared after you wrote
 17 your report and your report was served on
 18 Monsanto; correct?
 19 A. Yes.
 20 Q. Is it fair to say that the articles
 21 on this list you did not rely on in
 22 preparing your report?
 23 MS. FORGIE: Objection.
 24 THE WITNESS: Well, many of the
 25 articles on this are articles I pulled

Page 20

1 to learn about hepatitis B and hepatitis
 2 C. I didn't include them all in my
 3 report, although I read them all. I
 4 guess I don't really need to rely on
 5 them for purposes of my testimony.
 6 BY MS. DU PONT:
 7 Q. So the main references that you are
 8 relying on for purposes of your testimony
 9 are those references that you included in
 10 the Hardeman specific report itself?
 11 A. Yes.
 12 Q. And you had reviewed some of the
 13 references on this addendum prior to serving
 14 your report, and you believe that you
 15 considered those materials but you are not
 16 necessarily relying on them for your
 17 opinions; is that accurate?
 18 A. Yes.
 19 Q. Okay. I think you can set that
 20 aside.
 21 Now, did counsel for Mr. Hardeman
 22 provide you with any memo or memos regarding
 23 Mr. Hardeman's Roundup exposure?
 24 A. No, just the fact sheet. The fact
 25 sheet.

Page 21

1 Q. Okay. Let's take a look now at
 2 your report that you served in the Hardeman
 3 matter. We have marked Dr. Dennis
 4 Weisenburger's report under Hardeman versus
 5 Monsanto as Exhibit 7.
 6 (Exhibit Number 7 was marked
 7 for identification.)
 8 BY MS. DU PONT:
 9 Q. And is this your report in the
 10 Hardeman matter, Dr. Weisenburger?
 11 A. Yes.
 12 Q. And this report discloses all the
 13 opinions that you intend to offer at trial
 14 in Mr. Hardeman's case?
 15 A. Yes. There are a couple errors in
 16 the report. I don't know whether you want
 17 to talk about them now or later.
 18 Q. You can go ahead and tell me what
 19 the errors are now.
 20 A. So on the third written page at the
 21 end of the second paragraph, I see the
 22 latency is 29 years. It's actually
 23 26 years. The first sentence of the
 24 paragraph says 26 years. The end
 25 paragraph says 29 years. It should be

Page 22

1 26 years.
 2 Q. You're saying his exposure to
 3 Roundup in this case should be 26 years and
 4 not 29 years?
 5 A. Yes.
 6 MS. FORGIE: It's a typo
 7 because the top says 26 years.
 8 MS. DU PONT: Yes.
 9 THE WITNESS: The other
 10 correction is the odds ratio for BMI. I
 11 put down the wrong odds ratio. I wrote
 12 down 1.14. It should be 1.27.
 13 BY MS. DU PONT:
 14 Q. And is the confidence interval,
 15 does that also need to be corrected?
 16 A. Yes. The confidence interval is
 17 1.09-1.47.
 18 Q. And what I'll do later is we can
 19 take a look at the reference that you're
 20 relying on and understand where you're
 21 getting those numbers.
 22 A. Okay.
 23 Q. Do you have any other corrections
 24 that you want to make to your report at this
 25 time?

Page 23

1 A. No.
 2 Q. And your report along with your
 3 reliance list discloses all of the bases for
 4 the opinions you intend to offer in
 5 Mr. Hardeman's case?
 6 MS. FORGIE: Objection.
 7 THE WITNESS: Yes.
 8 BY MS. DU PONT:
 9 Q. Did you, in your preparation of
 10 this report, review any case-specific expert
 11 reports for Mr. Hardeman's other
 12 case-specific experts?
 13 A. No.
 14 Q. Did you review any of
 15 Mr. Hardeman's other case-specific expert
 16 reports after you prepared the report?
 17 A. I did review the rough draft of the
 18 Nabhan deposition.
 19 Q. Did you review the case-specific
 20 report in the Hardeman matter?
 21 A. No.
 22 Q. And anything you disagreed with
 23 that Dr. Nabhan said at his deposition?
 24 A. Not that I remember.
 25 Q. Had you actually, prior to writing

Page 24

1 your Hardeman-specific report, reviewed
 2 Dr. Nabhan's generic testimony in the MDL?
 3 A. You mean his general causation
 4 testimony?
 5 Q. Yes.
 6 A. I did review some of -- I don't
 7 remember exactly what I reviewed, but I did
 8 review some materials from him, yes. I
 9 don't know whether it was his report or a
 10 deposition. I don't remember.
 11 MS. FORGIE: I'm going to
 12 object to this. It's going into general
 13 causation.
 14 MS. DU PONT: I'm just
 15 inquiring whether he read other
 16 testimony from Dr. Nabhan who's a
 17 case-specific expert in his report.
 18 BY MS. DU PONT:
 19 Q. On Exhibit A, if you want to refer
 20 to Exhibit 2 which was your supplemental
 21 list, I'll just note that you did list under
 22 76 on that supplemental list that you
 23 disclosed as part of the Hardeman record the
 24 deposition transcripts and exhibits of
 25 Dr. Nabhan taken on August 23, 2017.

Page 25

1 A. Where is that? Oh, okay.
 2 Q. Take a look at Reference Number 76.
 3 Just confirm for me that you did, in fact,
 4 review his August, 2017, testimony.
 5 MS. FORGIE: Objection.
 6 THE WITNESS: Yes, I did.
 7 BY MS. DU PONT:
 8 Q. Okay. Do you generally agree with
 9 the testimony that Dr. Nabhan gave in the
 10 Hardeman matter, the rough draft that you
 11 reviewed?
 12 MS. FORGIE: Objection. Asked
 13 and answered.
 14 THE WITNESS: Yes.
 15 BY MS. DU PONT:
 16 Q. You don't intend to offer at trial
 17 any opinions that are not disclosed in the
 18 expert report that we've marked as
 19 Exhibit 7; correct?
 20 MS. FORGIE: Objection.
 21 THE WITNESS: Correct.
 22 BY MS. DU PONT:
 23 Q. Let's talk about how you prepared
 24 your report in this case. Am I correct that
 25 you prepared the report yourself?

Page 26

1 A. Yes.

2 Q. And how long did you spend drafting

3 the report?

4 A. Hours. Many hours.

5 Q. Do you remember how many?

6 A. Well, most of my first --

7 Q. 32 hours were spent?

8 A. -- 32 hours were spent researching

9 it and writing it and correcting it.

10 Q. Describe your process for drafting

11 your report.

12 A. [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 Q. Okay.

25 A. Considered the literature on

Page 27

1 obesity and overweight.

2 Q. Okay. So let's talk a little bit

3 about the telephone interview that you had

4 with Mr. Hardeman. That took place on

5 November 1, 2018; is that right?

6 A. Yes, yes.

7 Q. And do you understand that was

8 prior to when Mr. Hardeman was deposed in

9 this matter?

10 A. Yes.

11 Q. How long did the telephone call

12 last that you had with Mr. Hardeman?

13 A. It was about an hour, more or less.

14 I don't remember exactly.

15 Q. If you billed for an

16 hour-and-a-half on November 1, would that

17 hour-and-a-half have been for your phone

18 call with Mr. Hardeman, or was it additional

19 work as well?

20 A. It's probably additional work.

21 Maybe preparation before the phone call. I

22 didn't spend an hour-and-a-half on the phone

23 with him. I believe it was 45 minutes to an

24 hour.

25 Q. Was anyone else on the call besides

Page 28

1 yourself and Mr. Hardeman?

2 A. No.

3 Q. And did you take notes of that

4 phone call?

5 A. Yes.

6 Q. And did you rely on those notes in

7 preparing your report in this case?

8 MS. FORGIE: Objection.

9 THE WITNESS: Yes.

10 BY MS. DU PONT:

11 Q. And did you review those notes

12 prior to this deposition today?

13 A. Yes.

14 Q. And I would just request at this

15 time that counsel for Mr. Hardeman produce

16 the notes from Dr. Weisenburger's telephone

17 interview with Mr. Hardeman?

18 MS. FORGIE: I'm inclined not

19 to, but I'll talk to him at the break

20 about it and make a final addition.

21 MS. DU PONT: Thank you.

22 MS. FORGIE: Pursuant to

23 Pretrial Order Number 7 which states we

24 don't have to produce drafts.

25 MS. DU PONT: I would just

Page 29

1 maintain I'm not sure telephone

2 interview notes are drafts, but would be

3 more a reflection of the interview that

4 took place and not a draft report.

5 MS. FORGIE: It includes notes

6 as well.

7 BY MS. DU PONT:

8 Q. It looks like you spent about ten

9 hours prior to your phone call with

10 Mr. Hardeman working on his case based on

11 the invoice you provided. If you want to

12 take a look at it, feel free. It's

13 Exhibit 4.

14 A. That's correct.

15 Q. And what did you do for those ten

16 hours?

17 A. It was mainly reviewing the medical

18 record and the fact sheet, which at that

19 time, I think that's all I had.

20 Q. Okay. You mentioned already that

21 your telephone conversation, one of the

22 things you talked to him about was his

23 exposures. What did you mean by that?

24 A. His use of Roundup, how did he use

25 Roundup.

Page 34

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

Page 36

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

Page 35

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 MS. FORGIE: Objection.

20 [REDACTED]

Page 37

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 MS. FORGIE: Objection. Asked
and answered. You can answer it again.

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

Page 42

1 MS. FORGIE: Yes, you are.
 2 MS. DU PONT: Let's move to a
 3 different topic.
 4 BY MS. DU PONT:
 5 Q. Mr. Hardeman's Roundup use. You
 6 agree that he was using it as a home user;
 7 correct?
 8 A. Yes.
 9 Q. He was not a farmer spraying it on
 10 his crops; correct?
 11 A. Correct.
 12 Q. And in your report, you discuss for
 13 a couple pages what his Roundup use was and
 14 what his exposure was; correct?
 15 A. Yes.
 16 Q. And you mention that much of that
 17 discussion in your report came from the
 18 interview that you had with him in November
 19 of -- November 1, 2018; correct?
 20 A. Yes.
 21 Q. But you also read his deposition;
 22 right?
 23 A. I did.
 24 Q. And do you understand that there's
 25 some inconsistencies in what he said at his

Page 43

1 deposition versus what he told you at that
 2 interview on November 1?
 3 MS. FORGIE: Objection.
 4 THE WITNESS: Yes.
 5 BY MS. DU PONT:
 6 Q. Do you remember any of those
 7 inconsistencies right now, sitting here
 8 today?
 9 A. Yeah. So the main ones were that
 10 he told me he used the Roundup all
 11 year-round, pretty much every month. He
 12 used it intensively for about eight months
 13 and less intensively for the other four
 14 months.
 15 At his deposition, he changed that
 16 and said he used it intensively for about
 17 six months out of the year and that he used
 18 it less intensively only two months out of
 19 the year.
 20 So, yeah, there's some
 21 discrepancies that occurred. I can't
 22 explain those things. I didn't call him
 23 back and ask him what the truth was because
 24 by that time I had written my report.
 25 So, you know, sometimes people have

Page 44

1 difficulty remembering things. [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 I don't know what happened. When I
 5 questioned him, I was very careful to be as
 6 precise as I could, and this is the history
 7 that he gave to me. So whether it was one
 8 or the other, he still had significant
 9 exposures to Roundup.
 10 Q. So it's your understanding that
 11 when he gave his deposition under oath on
 12 November 8, 2018, that he testified that
 13 when he was spraying on the Forestville
 14 property, he was only spraying for about
 15 eight months per year; correct?
 16 MS. FORGIE: Objection.
 17 THE WITNESS: That's what he
 18 said.
 19 BY MS. DU PONT:
 20 Q. You did not note that discrepancy
 21 between his deposition transcript and your
 22 interview in your report; right?
 23 A. No, because I read his transcript
 24 after I wrote my report. So my report was
 25 already written and submitted.

Page 45

1 Q. Got it. So you reviewed his
 2 deposition transcript after the report was
 3 served on Monsanto?
 4 A. Yes.
 5 Q. Would you agree with me, though,
 6 that if we go by his testimony at his
 7 deposition, that in your report, you
 8 overestimated the amount of spraying that
 9 Mr. Hardeman was doing?
 10 MS. FORGIE: Objection.
 11 THE WITNESS: That's correct.
 12 BY MS. DU PONT:
 13 Q. [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 MS. FORGIE: Objection.
 21 THE WITNESS: No.
 22 BY MS. DU PONT:
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 46

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED].
 10 Q. Now, you wrote in your report that
 11 he would often get the spray on his hands,
 12 arms, face and sometimes mouth and sometimes
 13 he inhaled the mist while spraying.
 14 Do you recall writing that in your
 15 report?
 16 A. Yes.
 17 Q. Did you actually ask Mr. Hardeman
 18 in the interview how many times he got the
 19 spray on his arms, face, and mouth?
 20 A. It was frequent.
 21 Q. But did you also review
 22 Mr. Hardeman's deposition to see how many
 23 times he had spilled on himself?
 24 A. I can't remember the numbers, but
 25 it was less than what he told me.

Page 47

1 Q. So if he testified at his
 2 deposition that he spilled on himself about
 3 ten times, does that sound right?
 4 A. I don't remember what the
 5 deposition says. It was considerably less
 6 than what he told me.
 7 Q. But, again, if we went by what he
 8 said in his deposition, that would have been
 9 less exposure to Roundup; correct?
 10 MS. FORGIE: Objection.
 11 THE WITNESS: Well, I think
 12 people get exposed to Roundup when they
 13 use mist, whether they know it or not.
 14 Okay? So the fact that he -- what he
 15 told me was that he frequently got it on
 16 his hands and his arms when he was
 17 spraying from the truck and over the
 18 fence. It was common. That's what he
 19 told me.
 20 I don't understand him changing
 21 his story in the deposition. I wrote my
 22 report based on what he told me, and I
 23 believed it was true. If you deposed
 24 him today, he might tell you something
 25 totally different. I don't know.

Page 48

1 BY MS. DU PONT:
 2 Q. If we go by what he said in his
 3 deposition and what you've written in your
 4 report overestimates his exposure to
 5 Roundup; right?
 6 MS. FORGIE: Objection.
 7 THE WITNESS: Probably,
 8 although I think by him telling you that
 9 he only got it on his hands ten times,
 10 he's grossly underestimating his
 11 exposure.
 12 BY MS. DU PONT:
 13 Q. How do you know that?
 14 A. Because of the story. When you
 15 spray Roundup in a mist, you're going to get
 16 it on your hands. You're going to get it on
 17 your arms. You're going to get it on your
 18 clothes, just by the nature of what you're
 19 doing.
 20 Q. Have you sprayed Roundup before?
 21 A. No. I prefer 2,4-D, thank you.
 22 Q. What's your basis for saying that
 23 when you spray Roundup, you're going to get
 24 it on your hands?
 25 A. Because it happens to me when I

Page 49

1 spray 2,4-D.
 2 Q. But you don't have any personal
 3 experience spraying Roundup; correct?
 4 A. I don't.
 5 Q. Now, you understand that at his
 6 deposition, he also testified that he only
 7 inhaled Roundup about two or three times;
 8 correct?
 9 MS. FORGIE: Objection.
 10 THE WITNESS: I believe that's
 11 what he said. What did I say?
 12 Sometimes.
 13 BY MS. DU PONT:
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 A. Yes, I do.
 23 Q. Mr. Hardeman also explained to you
 24 that he would wash his hands if he spilled
 25 on himself; correct?

Page 50

1 A. So if he was mixing and he got it
 2 on his hands, he would wash it off with a
 3 hose. If he was out in the field spraying
 4 and he got it on his hands, he waited until
 5 he got back, which could have been one, two,
 6 three, four hours later.
 7 Q. But he would take a shower after
 8 that happened, if he spilled it on himself;
 9 correct?
 10 MS. FORGIE: Objection.
 11 THE WITNESS: Yes, he usually
 12 took a shower after spraying.
 13 BY MS. DU PONT:
 14 Q. Does the fact that someone washes
 15 the Roundup off of them after they've gotten
 16 it on their skin, does that decrease their
 17 exposure in your mind?
 18 A. Yes.
 19 Q. You agree that hepatitis C is a
 20 risk factor for non-Hodgkin's lymphoma;
 21 correct?
 22 A. Yes.
 23 Q. And it's also a risk factor for
 24 diffuse large B-cell lymphoma; correct?
 25 A. Yes.

Page 51

1 Q. In fact, in your report you mention
 2 that there's a 2 to 2.6-fold increased risk
 3 of diffused large B-cell non-Hodgkin's
 4 lymphoma with the infection of hepatitis C;
 5 correct?
 6 A. Yes.
 7 Q. Do you know what the latency is
 8 between exposure to hepatitis C virus and
 9 development of diffuse large B-cell
 10 lymphoma?
 11 A. There's one study that actually was
 12 able to look at that. It's probably
 13 somewhere between 6 and 8 years. These are
 14 in people with active hepatitis. So it's
 15 not very long, actually. Between 6 and
 16 8 years.
 17 Q. What study is that that you're
 18 referring to?
 19 A. It's one of the ones that I
 20 reference. I can't remember which one.
 21 Q. You can't remember, sitting here
 22 today, what reference it is that says the
 23 latency for hep C in development is 6 to
 24 8 years?
 25 A. I can't. It's one of the ones you

Page 52

1 reference, but I can't remember which one it
 2 was.
 3 Q. Is that the median?
 4 A. Yes, that's the median.
 5 Q. So if there's a bell curve, it can
 6 be much -- it could be shorter or it could
 7 be longer than 6 to 8 years; correct?
 8 A. Yes.
 9 Q. And do you recall what that
 10 reference says the bottom and the top of the
 11 bell curve are, sitting here right now?
 12 A. I can't remember whether they give
 13 that information.
 14 Q. Do you consider hepatitis C
 15 infection to be a causative risk factor for
 16 non-Hodgkin's lymphoma?
 17 MS. FORGIE: Objection.
 18 THE WITNESS: Yes, active
 19 hepatitis C infection. Chronic active
 20 hepatitis C infection.
 21 BY MS. DU PONT:
 22 Q. And do you consider chronic, active
 23 hepatitis C infection to be a causative risk
 24 factor for diffuse large B-cell lymphoma?
 25 MS. FORGIE: Objection.

Page 53

1 THE WITNESS: Yes.
 2 BY MS. DU PONT:
 3 Q. There are medical studies out there
 4 that actually discuss that infection with
 5 hepatitis C is not really a risk factor, but
 6 that it is a cause of diffuse large B-cell
 7 lymphoma; correct?
 8 A. Yes.
 9 Q. Are you familiar with the monograph
 10 from the International Agency for Research
 11 on Cancer regarding hep C?
 12 A. Yes.
 13 Q. But you did not cite that on any of
 14 your reference lists; correct?
 15 A. I didn't think I needed to.
 16 Q. And that's because it's redundant
 17 of your belief that hep C is a causative
 18 risk factor for non-Hodgkin's lymphoma?
 19 MS. FORGIE: Objection.
 20 THE WITNESS: It would be for
 21 the support. I've already accepted that
 22 as a fact in my report.
 23 BY MS. DU PONT:
 24 Q. Okay.
 25 A. I could have referenced it, but I

Page 54

1 didn't.
 2 Q. I'm going to go ahead and mark as
 3 Exhibit 8 the IARC monograph on hepatitis C.
 4 (Exhibit Number 8 was marked
 5 for identification.)
 6 MS. FORGIE: Whenever you're
 7 ready for a break.
 8 MS. DU PONT: We can finish
 9 this document, and we'll take a break.
 10 MS. FORGIE: Thanks.
 11 BY MS. DU PONT:
 12 Q. If you turn to page 158 of the
 13 monograph under Section 5, "Evaluation," do
 14 you see that there is sufficient -- that
 15 IARC writes, "There is sufficient evidence
 16 in humans for the carcinogenicity of chronic
 17 infection with HCV"?
 18 Did I read that correctly?
 19 A. Yes.
 20 Q. And they note, "Chronic infection
 21 with hepatitis C virus causes hepatocellular
 22 carcinoma and non-Hodgkin's lymphoma."
 23 Do you see that?
 24 A. Yes.
 25 Q. And then they go on to say,

Page 55

1 "Chronic infection with HCV is carcinogenic
 2 to humans Group 1."
 3 Do you see that?
 4 A. Yes.
 5 Q. So IARC concluded that there was
 6 sufficient evidence that chronic infection
 7 with the hepatitis C virus causes
 8 non-Hodgkin's lymphoma; correct?
 9 A. Yes.
 10 Q. And that chronic infection with the
 11 HCV or the hepatitis C virus is carcinogenic
 12 to humans Group 1; correct?
 13 A. Yes.
 14 Q. And we know that Mr. Hardeman had
 15 anywhere between 25 and 40 years of chronic
 16 hepatitis C infection prior to his diagnosis
 17 of non-Hodgkin's lymphoma; correct?
 18 MS. FORGIE: Objection.
 19 THE WITNESS: Correct.
 20 BY MS. DU PONT:
 21 Q. And do you understand that when
 22 IARC concludes that there is sufficient
 23 evidence of carcinogenicity with respect to
 24 a virus or any substance, that that means
 25 that there's a positive relationship that

Page 56

1 has been observed between the exposure and
 2 the cancer in studies in which chance, bias,
 3 and confounding could be ruled out with
 4 reasonable confidence?
 5 Do you understand that that's their
 6 definition?
 7 A. Yes.
 8 Q. So with respect to hepatitis C, a
 9 positive relationship has been observed
 10 between exposure to chronic hepatitis C and
 11 cancer in studies in which chance, bias, and
 12 confounding could be ruled out with
 13 reasonable confidence; correct?
 14 A. Yes.
 15 Q. So is it fair to say that IARC's
 16 conclusion that chronic hepatitis C
 17 infection is a carcinogen is a stronger
 18 conclusion than IARC has put forth regarding
 19 glyphosate and carcinogenicity findings in
 20 humans?
 21 MS. FORGIE: Objection.
 22 THE WITNESS: Yes, they said
 23 HCV's a Group 1 and glyphosate is a
 24 Group 2A.
 25 ///

Page 57

1 BY MS. DU PONT:
 2 Q. And IARC has noted, with respect to
 3 glyphosate, that there is limited evidence
 4 of carcinogenicity in humans; correct?
 5 A. Yes.
 6 Q. And that's a lower standard than
 7 what they found here, which is sufficient
 8 evidence in humans with HCV infection and
 9 non-Hodgkin's lymphoma; correct?
 10 A. Correct.
 11 MS. DU PONT: We can take a
 12 break now.
 13 MS. FORGIE: Thank you.
 14 THE VIDEOGRAPHER: The time is
 15 9:30 a.m., and we are off the record.
 16 (Recess taken from 9:31 a.m.
 17 to 9:41 a.m.)
 18 THE VIDEOGRAPHER: The time is
 19 now 9:41 a.m., and we are back on the
 20 record.
 21 BY MS. DU PONT:
 22 

Page 66

1 [REDACTED]

2 THE WITNESS: It's not really

3 clear to me what they're trying to say.

4 Are they trying to say that one is

5 better than the other? It's clear that

6 the viral RNA is a better test than the

7 other, based on the other studies that I

8 cite.

9 So it just depends on your

10 methodology and what -- in some studies,

11 how much money you have to do the

12 testing.

13 So you have to make -- you have

14 to make decisions based on a variety of

15 parameters. They could have done a

16 meta-analysis on the smaller group that

17 just had the RNA. And they could have

18 done that. They didn't do it.

19 BY MS. DU PONT:

20 Q. So the authors actually looked at

21 whether or not just having the HCV RNA

22 findings impacted the results.

23 I'll refer you to page 2083, the

24 last paragraph on the right-hand column.

25 The authors state, "Another possible

Page 67

1 source" -- do you see where I'm reading

2 from?

3 A. 2083 where?

4 Q. The last paragraph.

5 A. Yeah, okay.

6 Q. "Another possible source of

7 heterogeneity between studies could be the

8 definition of HCV infection that was not

9 consistent across studies or different

10 illicit generations used."

11 Then they note that some studies --

12 they basically say various studies are

13 defining HCV positivity differently.

14 They note that when only studies

15 using third-generation ELISA were included,

16 the pooled relative risk was 2.5, suggesting

17 that the HCV definition and ELISA generation

18 neither explained the heterogeneity between

19 studies nor adduced substantial bias; right?

20 A. I don't know. I'd have to reread

21 this again.

22 Q. Basically when they tried to --

23 when they did further analysis and

24 controlled for the different types of

25 studies, they didn't see inconsistent

Page 68

1 results when they were only looking at

2 sub-groups within their meta-analysis;

3 correct?

4 MS. FORGIE: Wait. Objection.

5 Asked and answered. You just asked that

6 question.

7 You can answer it again.

8 THE WITNESS: So I'd like to

9 read the paragraph.

10 BY MS. DU PONT:

11 Q. Okay.

12 A. I have to read it to understand it.

13 MS. FORGIE: You can read as

14 much as you need. You can read the

15 whole study if you need to.

16 THE WITNESS: So what they're

17 saying is that they had substantially

18 the same finding, whether they looked at

19 just the antibody or they looked at just

20 the RNA.

21 BY MS. DU PONT:

22 Q. Right.

23 A. But they didn't do the critical

24 thing and look at the risk for those that

25 had the antibody but didn't have the RNA.

Page 69

1 Okay?

2 So you would expect that both risk

3 ratios would be increased because a subset

4 of those with the antibody, maybe a

5 substantial subset, have the RNA. Okay?

6 So this doesn't really address the

7 question that's posed in some of the other

8 studies. Okay?

9 Q. Okay.

10 A. It's saying you can measure both,

11 and you'll pretty much find the same thing

12 because everybody -- because many people who

13 have the antibody also have the DNA -- or

14 the RNA.

15 So it doesn't really -- it doesn't

16 really -- they could have done this. They

17 could have taken the cases that had just the

18 antibody and didn't have the RNA and they

19 probably would have found what the other

20 papers I cite found, that the people with

21 just the antibody do not have an elevated

22 risk.

23 Q. Okay. You can put that aside.

24 Now, you also cite an article by

25 Mahale entitled, "The Effect of Sustained

Page 70

1 Virological Response on the Risk of
 2 Extrahepatic Manifestations of Hepatitis C
 3 Virus Infection."
 4 A. In my report?
 5 Q. In your supplemental list.
 6 A. Okay.
 7 MS. FORGIE: Is this 10?
 8 MS. DU PONT: Yes, sorry. This
 9 is Exhibit 10.
 10 (Exhibit Number 10 was marked
 11 for identification.)
 12 BY MS. DU PONT:
 13 Q. And this was included on your
 14 supplemental list. Now, do you know if you
 15 had reviewed this article prior to drafting
 16 your report or after you had drafted your
 17 report?
 18 A. I don't know. I don't remember.
 19 Q. Okay. And the results of this
 20 paper in the conclusions on the second page,
 21 they say, "Risks of several extrahepatic
 22 manifestations of HCV infection are reduced
 23 after antiviral therapy with sustained viral
 24 response" -- sorry, "sustained virological
 25 response. However, early initiation of

Page 71

1 anti-viral therapy may be required to reduce
 2 the risk of glomerulonephritis,
 3 non-Hodgkin's lymphoma, and stroke."
 4 Do you see that?
 5 A. Yes.
 6 Q. And if we take a look at Figure 2
 7 on page 16, the authors are looking at
 8 several of what they call extrahepatic
 9 manifestations, one of which is not
 10 non-Hodgkin's lymphoma; right?
 11 A. Right.
 12 Q. What Figure 2D, which is referring
 13 to non-Hodgkin's lymphoma, is showing, is
 14 that over time, the longer you go without
 15 anti-viral treatment, there is no reduction
 16 in your risk of non-Hodgkin's lymphoma
 17 because of that treatment; correct?
 18 MS. FORGIE: Objection.
 19 THE WITNESS: Well, what they
 20 showed is that the most effective time
 21 to institute therapy is shortly after
 22 the diagnosis. Then you see actually a
 23 decrease in risk.
 24 BY MS. DU PONT:
 25 [REDACTED]

Page 72

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 73

1 [REDACTED]
 2 [REDACTED]
 3 MS. FORGIE: Objection.
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 MS. FORGIE: Objection.
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 74

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 76

1 [REDACTED]
 2 BY MS. DU PONT:
 3 Q. And in your report, you note that
 4 the hepatitis B virus increases the risk of
 5 non-Hodgkin's lymphoma by approximately
 6 twofold; right?
 7 A. Right.
 8 Q. And you cite some articles to
 9 support that in your report?
 10 A. Correct.
 11 Q. And are you aware that the
 12 International Agency For Research on Cancer
 13 has looked at the hepatitis B virus and
 14 whether or not it is a human carcinogen for
 15 non-Hodgkin's lymphoma?
 16 Are you aware of that?
 17 A. I know they looked at it for a
 18 cellular carcinoma, but I don't believe
 19 they've looked at it for non-Hodgkin's
 20 lymphoma.
 21 Q. Okay.
 22 A. I think they actually do mention in
 23 their conclusions that there were some
 24 studies that showed increased risk for
 25 non-Hodgkin's lymphoma, but they didn't --

75

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 77

1 the firm conclusion was really about
 2 hepatocellular carcinoma.
 3 Q. They also noted positive
 4 association between chronic infection with
 5 HPV and non-Hodgkin's lymphoma; fair?
 6 A. Yes, they did.
 7 Q. And they classify hepatitis B as a
 8 Class 1 human carcinogen; correct?
 9 A. Yes.
 10 MS. FORGIE: Objection.
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

1 So can we go off the record for a
 2 second?
 3 (Discussion off the record.)
 4 THE VIDEOGRAPHER: The time is
 5 now 10:15 a.m., and we are off the
 6 record.
 7 (Recess taken from 10:15 a.m.
 8 to 10:29 a.m.)
 9 THE VIDEOGRAPHER: The time is
 10 now 10:29 a.m., and we're back on the
 11 record.
 12 BY MS. DU PONT:

13 Q. [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 ///

1 The abstract, I think, is --
 2 Q. It flips them in the abstract.
 3 A. It flips them in the abstract; so
 4 that's an error. There's an error
 5 somewhere, and we don't really know for sure
 6 where the error is.
 7 Q. So are these based on Table 3, the
 8 relative risk -- the unadjusted relative
 9 risk for males that are overweight with
 10 diffuse large B-cell lymphoma is 1.27 and
 11 the adjusted relative risk is actually 1.34;
 12 correct?
 13 A. Yes.
 14 Q. And explain to me why you are
 15 relying on the unadjusted number and not the
 16 adjusted number.
 17 A. I could have relied on either one.
 18 It doesn't truly matter to me.
 19 Q. Okay. And elsewhere, in this
 20 paper, it notes that the relative risks of
 21 diffuse large B-cell lymphoma in obese men
 22 and women was 1.4 and 1.34, respectively.
 23 That's in the abstract.
 24 Do you see that?
 25 A. It says, "The relative risk of

1 (Exhibit Number 11 was marked
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 Q. And can you just refer me to the
 10 number that you are correct -- where in this
 11 article you've gotten the new number that
 12 you've corrected in your report?
 13 A. Yeah, it's page 126, Table 3, which
 14 is the table on overweight. If you go down
 15 on the second column, about the middle, it
 16 says, "Male," and then you go across, it's
 17 1.27. With odds ratio -- 1.27 with a
 18 95 percent confidence interval load of 1.09
 19 to 1.47.
 20 That's what I was quoting.
 21 Actually, the paper confuses the odds
 22 ratios. In some places, it reverses them.
 23 So it's hard to know what to rely on.
 24 But I think this agreed with the
 25 text so that's, in the end, what I used.

1 diffuse large B-cell lymphoma in overweight
 2 men and women was 1.22 and 1.27,
 3 respectively."
 4 The number for men is wrong.
 5 Q. Right.
 6 A. So they just flipped those two, I
 7 think, is what they did.
 8 Q. But I'm actually referring to later
 9 in the text where they're talking about
 10 obese men and women with diffuse large
 11 B-cell lymphoma, and they report relative
 12 risks of 1.4 and 1.34 in the abstract.
 13 Do you see that?
 14 A. Yes, yes. They didn't report the
 15 adjusted odds ratios either in the abstract.
 16 Q. Right. So the -- and in Table 4,
 17 the relative risk for obese -- this is on
 18 page 127, "The relative risk for obesity and
 19 diffuse large B-cell lymphoma in males is
 20 1.4"; correct?
 21 A. Yes.
 22 Q. Okay. You can set that aside.
 23 We talked at your deposition the
 24 other day about how age is a risk factor for
 25 non-Hodgkin's lymphoma.

1 [REDACTED]
2 [REDACTED]
3 [REDACTED]
4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 [REDACTED]
8 [REDACTED]
9 [REDACTED]
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]

16 MS. FORGIE: Objection. Even
17 though you phrased it as hard, it's a
18 general causation.

19 THE WITNESS: It's a study
20 of -- I'm trying to remember, skin,
21 tumors in mice, where they initiated the
22 tumors with a chemical other than
23 glyphosate and then they introduced
24 glyphosate. So there's one study that
25 suggests glyphosate is a promoter.

1 BY MS. DU PONT:

2 Q. Sitting here today, other than that
3 one study, you cannot reference for me an
4 additional study that suggests that
5 glyphosate is a promoter; correct?

6 MS. FORGIE: Objection.
7 General causation.

8 THE WITNESS: No, but there are
9 many studies that have now demonstrated
10 that glyphosate or Roundup are genotoxic
11 agents and so certainly has the
12 potential to be an initiator or a
13 promoter, or both.

14 BY MS. DU PONT:

15 Q. But because something is genotoxic,
16 that suggests it is causing DNA damage;
17 correct?

18 MS. FORGIE: Objection.
19 Causation.

20 THE WITNESS: Right.

21 BY MS. DU PONT:

22 Q. And that's different from
23 promotion; correct?

24 MS. FORGIE: Objection.
25 General causation.

1 THE WITNESS: Well, promotion
2 is just what happens after initiation to
3 make the cell move to become a true
4 cancer cell, and that could be things
5 that initiate proliferation, genetic
6 events that prevent the cell from dying,
7 or additional genotoxic events that give
8 additional mutations that eventually
9 move the cell along to becoming a cancer
10 cell.

11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]

16 MS. FORGIE: Objection. Asked
17 and answered.

18 [REDACTED]
19 [REDACTED]
20 [REDACTED]
21 [REDACTED]
22 [REDACTED]
23 [REDACTED]
24 [REDACTED]
25 [REDACTED]

1 [REDACTED]
2 [REDACTED]
3 [REDACTED]
4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 [REDACTED]
8 [REDACTED]
9 [REDACTED]
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]
16 [REDACTED]
17 [REDACTED]
18 [REDACTED]
19 [REDACTED]
20 [REDACTED]
21 [REDACTED]
22 [REDACTED]
23 [REDACTED]
24 [REDACTED]
25 [REDACTED]

25 ///

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 MS. DU PONT: Objection.
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 Q. Do you consider yourself an expert
 5 in the causes of non-Hodgkin's lymphoma?
 6 A. Yes.
 7 Q. In fact, you've published over 50
 8 papers in peer-reviewed journals about the
 9 causes of non-Hodgkin's lymphoma; correct?
 10 A. Yes.
 11 MS. DU PONT: Objection. Form.
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 MS. DU PONT: Objection. Form.
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

1 [REDACTED]
 2 [REDACTED]
 3 [REDACTED]
 4 [REDACTED]
 5 [REDACTED]
 6 [REDACTED]
 7 [REDACTED]
 8 [REDACTED]
 9 [REDACTED]
 10 [REDACTED]
 11 [REDACTED]
 12 [REDACTED]
 13 [REDACTED]
 14 [REDACTED]
 15 [REDACTED]
 16 [REDACTED]
 17 [REDACTED]
 18 [REDACTED]
 19 [REDACTED]
 20 [REDACTED]
 21 [REDACTED]
 22 [REDACTED]
 23 [REDACTED]
 24 [REDACTED]
 25 [REDACTED]

Page 110

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 MS. DU PONT: Objection. Form.

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

Page 112

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

25 MS. DU PONT: Object to form.

Page 111

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

25 [REDACTED]

Page 113

1 MS. FORGIE: That's all I have.

2 MS. DU PONT: Just give me one

3 minute.

4 THE VIDEOGRAPHER: The time is

5 now 10:55 a.m., and we are off the

6 record.

7 (Recess taken from 10:55 a.m.

8 to 10:57 a.m.)

9 THE VIDEOGRAPHER: The time is

10 now 10:57 a.m., and we are back on the

11 record.

12

13 FURTHER EXAMINATION

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 [REDACTED]

21 [REDACTED]

22 [REDACTED]

23 [REDACTED]

24 [REDACTED]

25 [REDACTED]

Page 114

1 [REDACTED]

2 [REDACTED]

3 [REDACTED]

4 [REDACTED]

5 [REDACTED]

6 [REDACTED]

7 [REDACTED]

8 [REDACTED]

9 [REDACTED]

10 [REDACTED]

11 [REDACTED]

12 [REDACTED]

13 [REDACTED]

14 [REDACTED]

15 [REDACTED]

16 [REDACTED]

17 [REDACTED]

18 [REDACTED]

19 [REDACTED]

20 MS. DU PONT: Okay. I have no

21 further questions.

22 MS. FORGIE: Nothing else.

23 THE VIDEOGRAPHER: The time is

24 now 10:58 a.m., and we are off the

25 record.

Page 115

1 (Whereupon the deposition

2 concluded at 10:58 a.m.)

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Page 116

1 REPORTER'S CERTIFICATE

2

3 The undersigned Certified Shorthand

4 Reporter licensed in the State of California

5 does hereby certify:

6 That the foregoing deposition was

7 taken before me at the time and place

8 therein set forth, at which time the witness

9 was duly sworn by me;

10 That the testimony of the witness

11 and all objections made at the time of the

12 examination were recorded stenographically

13 by me and were thereafter transcribed, said

14 transcript being a true copy of my shorthand

15 notes thereof.

16 I further declare that I have no

17 interest in the outcome of the action.

18 In witness whereof, I have

19 subscribed my name this 20th day of

20 December, 2018.

21

22

23 _____

24 LISA MOSKOWITZ

25 CSR 10816, RPR, CRR, CLR
NCRA Realtime Systems Administrator

Page 117

1 INSTRUCTIONS TO WITNESS

2

3 Please read your deposition over

4 carefully and make necessary corrections.

5 You should state the reason in the

6 appropriate space on the errata sheet for

7 any corrections that are made.

8 After doing so, please sign the

9 errata sheet and date it.

10 You are signing same subject to the

11 changes you have noted on the errata sheet,

12 which will be attached to your deposition.

13 It is imperative that you return

14 the original errata sheet to the deposing

15 attorney within thirty (30) days of receipt

16 of the deposition transcript by you. If you

17 fail to do so, the deposition transcript may

18 be deemed to be accurate and may be used in

19 court.

20

21

22

23

24

25

1 ERRATA SHEET
 2 -----
 3
 4 PAGE LINE CHANGE
 5 _____
 6 REASON: _____
 7 _____
 8 REASON: _____
 9 _____
 10 REASON: _____
 11 _____
 12 REASON: _____
 13 _____
 14 REASON: _____
 15 _____
 16 REASON: _____
 17 _____
 18 REASON: _____
 19 _____
 20 REASON: _____
 21 _____
 22 REASON: _____
 23 _____
 24 REASON: _____
 25 _____

1 LAWYER'S NOTES
 2 PAGE LINE
 3 _____
 4 _____
 5 _____
 6 _____
 7 _____
 8 _____
 9 _____
 10 _____
 11 _____
 12 _____
 13 _____
 14 _____
 15 _____
 16 _____
 17 _____
 18 _____
 19 _____
 20 _____
 21 _____
 22 _____
 23 _____
 24 _____
 25 _____

1 ACKNOWLEDGMENT OF DEPONENT
 2
 3 I, DENNIS WEISENBURGER, M.D., do
 4 hereby certify that I have read the
 5 foregoing pages, 1-119, and that the same is
 6 a correct transcription of the answers given
 7 by me to the questions therein propounded,
 8 except for the corrections or changes in
 9 form or substance, if any, noted in the
 10 attached Errata Sheet.
 11
 12
 13 _____
 14 DENNIS WEISENBURGER, M.D. DATE
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25

Blank area for notes or additional text on page 119.